These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22336089)

  • 1. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
    Mastropaolo J; Rosse RB; Deutsch SI
    Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.
    Wallace TL; Bertrand D
    Expert Opin Ther Targets; 2013 Feb; 17(2):139-55. PubMed ID: 23231385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
    Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
    Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
    Kuepper R; Skinbjerg M; Abi-Dargham A
    Handb Exp Pharmacol; 2012; (212):1-26. PubMed ID: 23129326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
    Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U
    Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?
    Bencherif M; Lippiello PM
    Med Hypotheses; 2010 Feb; 74(2):281-5. PubMed ID: 19800174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.
    Javanbakht A
    Med Hypotheses; 2006; 67(5):1173-84. PubMed ID: 16824690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
    Berger PA
    J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development.
    Janhunen S; Ahtee L
    Neurosci Biobehav Rev; 2007; 31(3):287-314. PubMed ID: 17141870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.